Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kessel-Lo – page 90

1 979 clinical trials in Kessel-Lo, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kessel-Lo at a glance
1 979
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 979 trials in Kessel-Lo

Open in trial search

Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Arteriosclerosis

Not recruiting

Safety, Tolerability and Pharmacokinetics of Single Oral Dose of MK-1403 and Famotidine in Healthy Male Participants with Atherosclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Famotidine
  • Sponsor:Merck Sharp & Dohme LLC
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Aticaprant
  • Sponsor:Janssen Cilag International

Pain

Not recruiting

Safety, Tolerability and Pharmacokinetics of MK-4318 in Healthy Adults with Pain

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:MK-4318
  • Sponsor:Merck Sharp & Dohme LLC

A study to evaluate the taste of sisunatovir and denatonium benzoate in healthy adults for the treatment of respiratory syncytial virus (RSV)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Denatonium benzoate
  • Sponsor:Pfizer Inc.

Osteosarcoma

Not recruiting

Efficacy and Safety of Maintenance Cabozantinib Plus Best Supportive Care in Pediatric and AYA Patients with Unresectable Residual Osteosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cabozantinib
  • Sponsor:Ipsen Innovation

A study to evaluate how lazertinib is absorbed in healthy adults to support future treatment for non-small cell lung cancer.

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Lazertinib
  • Sponsor:Janssen Cilag International

COVID-19

Not recruiting

PF-07817883 Oral Tablet Bioavailability Study in Healthy Adults to Support Treatment of COVID‑19

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Metastatic neoplasm

Not recruiting

Phase 1 Study of NG-641 with Nivolumab and Pembrolizumab in Patients with Metastatic or Advanced Epithelial Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:NG-641
  • Sponsor:Akamis Bio Limited

Hepatitis D

Not recruiting

A Study of Brelovitug Compared to Delayed Treatment in Patients with Chronic Hepatitis Delta Infection

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

A Study of Mevrometostat and Enzalutamide for Men with Metastatic Castration-Sensitive Prostate Cancer Who Have Not Received Hormonal Therapy or Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Prostate cancer

Not recruiting

Study of xaluritamig compared to cabazitaxel or androgen receptor therapy for patients with metastatic castration-resistant prostate cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kessel-Lo

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for common digestive conditions.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Methods

The study evaluates various therapeutic approaches, including on-demand medication and alginate-based alternatives, to optimize treatment protocols for patients with digestive disorders.

02 Primary Care Innovation

Research examining optimal medication reduction strategies in primary care settings, with a focus on improving long-term patient outcomes and reducing unnecessary medication use.

  • Medication Optimization
  • Patient-Centered Care
  • Therapeutic Alternative Assessment

This initiative aims to establish evidence-based guidelines for discontinuing long-term medications when they may no longer be clinically indicated.

03 Treatment Comparison Studies

Comparative research evaluating the effectiveness of different deprescribing approaches in managing common gastrointestinal conditions.

  • Medication Withdrawal Strategies
  • Alternative Treatment Methods
  • Clinical Outcome Assessment

The research compares traditional dose reduction methods with newer therapeutic strategies to determine optimal treatment pathways.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.